SUPPORTING INNOVATIVE DRUG DISCOVERY RESEARCH IN ALZHEIMER’S DISEASE
The goal of the Thome Memorial Foundation Awards Program in Alzheimer’s Disease Drug Discovery Research is to support innovative drug discovery research that will lead to improved therapies for individuals suffering from Alzheimer’s disease.
Researchers dedicated to the validation and testing of target compounds and therapeutic agents including biologics and small molecules, are encouraged to apply. Consideration will be given to research focused on pathogenic mechanisms including inflammatory response, synaptic toxicity, neuronal toxicity, and endosomal/lysosomal trafficking defects. (NOTE: The sentence in bold was corrected to reflect the 2017 Research Focus. Please make sure you’re using the Updated Guidelines that highlight this change).
Basic research or new target discovery, genetic studies, biomarker research, neuro-imaging and clinical studies are currently outside the scope of this Program.
All applicants must hold a faculty appointment at a non-profit academic, medical, non-governmental or research institution in the United States. US citizenship is not required. Applicants do not need to be nominated by their institutions. Preference will be given to originality of ideas, regardless of faculty seniority.
For complete Eligibility Requirements and Application Instructions, download the Guidelines available to the right.